N-acetyl-seryl-aspartyl-lysyl-proline Inhibits Diabetes-Associated Kidney Fibrosis and Endothelial-Mesenchymal Transition

Figure 4

AcSDKP inhibits EndMT in the diabetic kidney. ((a)–(e)) Immunolabeling for FSP1 and CD31 in a kidney from each group of mice. Arrows indicate cells that are double-labeled for FSP1 and CD31. ((f)–(j)) Immunolabeling for αSMA and CD31 in a kidney from each group of mice. Arrows indicate cells that are double-labeled for αSMA and CD31. Merged images with DAPI-stained nuclei are shown. Scale bar: 25 μm. ((k), (l)) Quantification of cells undergoing EndMT. FSP1 and CD31 double-labeled cells (k) and αSMA and CD31 double-labeled cells (l) in each visual field were imaged using fluorescence microscopy and quantified. The data are expressed as the mean ± SEM values. Diabetes is designated as DM. For all of the groups except the group that received TA-606 (𝑛=3), 𝑛=5 mice were analyzed.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)